Therapeutic effects of histone deacetylase inhibitors on kidney disease

다국어 초록 (Multilingual Abstract)

Increasing evidence has shown the involvementof histone deacetylases (HDACs) in the development andprogression of various renal diseases, highlighting itsinhibition as a promising therapeutic strategy to preventkidney diseases. Accordingly, numerous studies haveshown that HDAC inhibitors protect the kidneys fromvarious diseases through their effects on multiple pathways,such as suppression of transforming growth factor-βsignaling pathway and nuclear factor-κB signaling pathways,augmentation of apoptosis, and inhibition of angiogenesis.
To develop more effective and less toxic isoformselectiveHDAC inhibitors and further improve clinicaloutcomes, it is necessary to identify and understand themechanisms involved in the pathogenesis and progressionof renal diseases. This review focuses on the roles ofHDAC inhibitors and the mechanisms involved in theirtherapeutic effects in experimental models of kidney diseasesincluding glomerulosclerosis, tubulointerstitialfibrosis, glomerular and tubulointerstitial inflammation,lupus nephritis, polycystic kidney disease, and renal cellcarcinoma (RCC).

참고문헌 (Reference)

1 Drugs@FDA,

2 ClinicalTrials.gov.,

3 Senturk E, "p53 and cell cycle effects after DNA damage" 962 : 49-61, 2013

4 Broude EV, "p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation" 26 : 6954-6958, 2007

5 Abbas T, "p21 in cancer: intricate networks and multiple activities" 9 : 400-414, 2009

6 Laplante M, "mTOR signaling in growth control and disease" 149 : 274-293, 2012

7 MacDonald BT, "Wnt/beta-catenin signaling: components, mechanisms, and diseases" 17 : 9-26, 2009

8 Komiya Y, "Wnt signal transduction pathways" 4 : 68-75, 2008

9 Mahalingam D, "Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels" 16 : 141-153, 2010

10 Khan S, "Valproate attenuates the proteinuria, podocyte and renal injury by facilitating autophagy and inactivation of NF-${\kappa}B$/iNOS signaling in diabetic rat" 110 : 1-16, 2015

11 Chang JW, "Upregulation of SIRT1 reduces endoplasmic reticulum stress and renal fibrosis" 133 : 116-128, 2016

12 Choi SY, "Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes" 72 : 130-140, 2015

13 Yoshikawa M, "Trichostatin a prevents TGF-beta1-induced apoptosis by inhibiting ERK activation in human renal tubular epithelial cells" 642 : 28-36, 2010

14 Tung CW, "Trichostatin A ameliorates renal tubulointerstitial fibrosis through modulation of the JNK-dependent Notch-2 signaling pathway" 7 : 14495-, 2017

15 Hricik DE, "Transplant immunology and immunosuppression: core curriculum 2015" 65 : 956-966, 2015

16 Wang W, "Transforming growth factor-beta and Smad signalling in kidney diseases" 10 : 48-56, 2005

17 Loeffler I, "Transforming growth factor-${\beta}$ and the progression of renal disease" 29 (29): i37-i45, 2014

18 Lee SY, "Therapeutic targets for treating fibrotic kidney diseases" 165 : 512-530, 2015

19 Kang SW, "Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis" 42 : 25-31, 2017

20 Sharma S, "The story of Notch and chronic kidney disease" 20 : 56-61, 2011

21 Asanuma K, "The role of podocytes in glomerular pathobiology" 7 : 255-259, 2003

22 Altucci L, "The promise of retinoids to fight against cancer" 1 : 181-193, 2001

23 Haberland M, "The many roles of histone deacetylases in development and physiology: implications for disease and therapy" 10 : 32-42, 2009

24 Park MJ, "The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats" 13 : 300-, 2016

25 Jones J, "The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo" 13 : 2376-2385, 2009

26 Talks KL, "The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages" 157 : 411-421, 2000

27 Hoesel B, "The complexity of NF-${\kappa}B$ signaling in inflammation and cancer" 12 : 86-, 2013

28 Wu WP, "The attenuation of renal fibrosis by histone deacetylase inhibitors is associated with the plasticity of FOXP3 IL-17 T cells" 18 : 225-, 2017

29 Plotnikov A, "The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation" 1813 : 1619-1633, 2011

30 Grynberg K, "The JNK signaling pathway in renal fibrosis" 8 : 829-, 2017

31 Levine MH, "Targeting Sirtuin-1 prolongs murine renal allograft survival and function" 89 : 1016-1026, 2016

32 Yu L, "TGF-beta isoforms in renal fibrogenesis" 64 : 844-856, 2003

33 Meng XM, "TGF-${\beta}$: the master regulator of fibrosis" 12 : 325-338, 2016

34 Samarakoon R, "TGF-${\beta}$ signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities" 25 : 264-268, 2013

35 Sureshbabu A, "TGF-${\beta}$ signaling in the kidney: profibrotic and protective effects" 310 : F596-F606, 2016

36 Raphael I, "T cell subsets and their signature cytokines in autoimmune and inflammatory diseases" 74 : 5-17, 2015

37 Mita AC, "Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics" 14 : 5000-5005, 2008

38 Zhang T, "Survivin-induced Aurora-B kinase activation: a mechanism by which APC mutations contribute to increased mitoses during colon cancer development" 177 : 2816-2826, 2010

39 Ma T, "Suppression of BMP-7 by histone deacetylase 2 promoted apoptosis of renal tubular epithelial cells in acute kidney injury" 8 : e3139-, 2017

40 Sato A, "Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically" 109 : 1258-1268, 2012

41 Sah NK, "Structural, functional and therapeutic biology of survivin" 244 : 164-171, 2006

42 Regna NL, "Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice" 162 : 58-73, 2016

43 Khan S, "Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat" 98 : 230-239, 2015

44 Khan S, "Sodium butyrate, a HDAC inhibitor ameliorates eNOS, iNOS and TGF-${\beta}1$-induced fibrogenesis, apoptosis and DNA damage in the kidney of juvenile diabetic rats" 73 : 127-139, 2014

45 Dong W, "Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC" 232 : 71-83, 2017

46 Okado T, "Smad7 mediates transforming growth factor-b-induced apoptosis in mesangial cells" 62 : 1178-1186, 2002

47 Veerasamy M, "Smad mediated regulation of inhibitor of DNA binding 2 and its role in phenotypic maintenance of human renal proximal tubule epithelial cells" 8 : e51842-, 2013

48 Wu J, "Skp2 is required for Aurora B activation in cell mitosis and spindle checkpoint" 14 : 3877-3884, 2015

49 Carafa V, "Sirtuin functions and modulation: from chemistry to the clinic" 8 : 61-, 2016

50 Zhou X, "Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease" 123 : 3084-3098, 2013

51 Huang W, "Sirt6 deficiency results inprogression of glomerular injury in the kidney" 9 : 1069-1083, 2017

52 Hasegawa K, "Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression" 372 : 51-56, 2008

53 Mimnaugh EG, "Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity" 3 : 551-566, 2004

54 Liu M, "Signalling pathways involved in hypoxia-induced renal fibrosis" 21 : 1248-1259, 2017

55 Kisseleva T, "Signaling through the JAK/STAT pathway, recent advances and future challenges" 285 : 1-24, 2002

56 Ron D, "Signal integration in the endoplasmic reticulum unfolded protein response" 8 : 519-529, 2007

57 Ren J, "Selective HDAC6 inhibition decreases early stage of lupus nephritis by down-regulating both innate and adaptive immune responses" 2017

58 Gumz ML, "Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma" 13 : 4740-4749, 2007

59 Xu S, "SIRT1/3 activation by resveratrol attenuates acute kidney injury in a septic rat model" 2016 : 7296092-, 2016

60 Wang YQ, "SIRT1 protects against oxidative stress-induced endothelial progenitor cells apoptosis by inhibiting FOXO3a via FOXO3a ubiquitination and degradation" 230 : 2098-2107, 2015

61 Kume S, "SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation" 282 : 151-158, 2007

62 Liu R, "Role of transcription factor acetylation in diabetic kidney disease" 63 : 2440-2453, 2014

63 Tang J, "Role of epidermal growth factor receptor in acute and chronic kidney injury" 83 : 804-810, 2013

64 Isono M, "Ritonavir interacts with belinostat to cause endoplasmic reticulum stress and histone acetylation in renal cancer cells" 24 : 327-335, 2016

65 Tang XH, "Retinoids, retinoic acid receptors, and cancer" 6 : 345-364, 2011

66 Touma SE, "Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model" 11 : 3558-3566, 2005

67 Juengel E, "Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo" 8 : e53100-, 2013

68 Wang S, "Renal bone morphogenetic protein-7 protects against diabetic nephropathy" 17 : 2504-2512, 2006

69 Tang Q, "Regulatory T-cell therapy in transplantation: moving to the clinic" 3 : a015552-, 2013

70 Zhuang S, "Regulation of STAT signaling by acetylation" 25 : 1924-1931, 2013

71 Cooper SJ, "Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers" 11 : 2105-2115, 2012

72 Klotz LO, "Redox regulation of FoxO transcription factors" 6 : 51-72, 2015

73 Overstreet JM, "Redox control of p53 in the transcriptional regulation of TGF-${\beta}1$ target genes through SMAD cooperativity" 26 : 1427-1436, 2014

74 Yung S, "Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis" 6 : 874-, 2017

75 Kinugasa F, "Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction" 23 : 18-23, 2010

76 Lan A, "Potential role of Akt signaling in chronic kidney disease" 30 : 385-394, 2015

77 Xia S, "Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts" 137 : 1075-1084, 2010

78 Katayama H, "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53" 36 : 55-62, 2004

79 Jiang BH, "Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1" 12 : 363-369, 2001

80 Sato A, "Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells" 14 : 71-, 2014

81 Singh BN, "Nonhistone protein acetylation as cancer therapy targets" 10 : 935-954, 2010

82 Sanz AB, "NF-kappaB in renal inflammation" 21 (21): 1254-1262, 2010

83 Liu Y, "Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation" 287 : 29168-29174, 2012

84 Lin CL, "MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction" 25 : 1698-1709, 2014

85 Amengual JE, "Mechanisms of acquired drug resistance to the HDAC6 selective inhibitor ricolinostat reveals rational drug-drug combination with ibrutinib" 23 : 3084-3096, 2017

86 Fournel M, "MGCD0103, a novel isotypeselective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo" 7 : 759-768, 2008

87 Advani A, "Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism" 178 : 2205-2214, 2011

88 Lu TC, "Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy" 76 : 63-71, 2009

89 Abecassis M, "Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference" 3 : 471-480, 2008

90 Jatiani SS, "Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies" 1 : 979-993, 2010

91 Brosius FC 3rd, "JAK inhibition and progressive kidney disease" 24 : 88-95, 2015

92 Andrawes MB, "Intrinsic selectivity of notch 1 for delta-like 4 over delta-like 1" 288 : 25477-25489, 2013

93 Bertrand P, "Inside HDAC with HDAC inhibitors" 45 : 2095-2116, 2010

94 Fan LX, "Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation" 81 : 76-85, 2012

95 Yoshikawa M, "Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells" 18 : 58-65, 2007

96 Pang M, "Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy" 297 : F996-F1005, 2009

97 Imai N, "Inhibition of histone deacetylase activates side population cells in kidney and partially reverses chronic renal injury" 25 : 2469-2475, 2007

98 Cebotaru L, "Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease" 90 : 90-99, 2016

99 Bali P, "Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors" 280 : 26729-26734, 2005

100 Nguyen-Thanh T, "Inhibition of histone deacetylase 1 ameliorates renal tubulointerstitial fibrosis via modulation of inflammation and extracellular matrix gene transcription in mice" 2017

101 Shi Y, "Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury" 312 : F502-F515, 2017

102 Samarakoon R, "Induction of renal fibrotic genes by TGF-${\beta}1$ requires EGFR activation, p53 and reactive oxygen species" 25 : 2198-2209, 2013

103 Kumari G, "Induction of p21CIP1 protein and cell cycle arrest after inhibition of Aurora B kinase is attributed to aneuploidy and reactive oxygen species" 289 : 16072-16084, 2014

104 Land SC, "Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif" 282 : 20534-20543, 2007

105 Beier UH, "Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells" 23 : 670-678, 2011

106 Yu Z, "Histone deacetylases augment cytokine induction of the iNOS gene" 13 : 2009-2017, 2002

107 de Ruijter AJ, "Histone deacetylases (HDACs): characterization of the classical HDAC family" 370 : 737-749, 2003

108 Ranganathan P, "Histone deacetylase-mediated silencing of AMWAP expression contributes to cisplatin nephrotoxicity" 89 : 317-326, 2016

109 Noh H, "Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury" 297 : F729-F739, 2009

110 Marumo T, "Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury" 298 : F133-F141, 2010

111 Fath DM, "Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha" 281 : 13612-13619, 2006

112 Mishra N, "Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse" 111 : 539-552, 2003

113 천부순, "Histone deacetylase inhibitors in hematological malignancies and solid tumors" 대한약학회 38 (38): 933-949, 2015

114 Dai Q, "Histone deacetylase inhibitors attenuate P-aIgA1-induced cell proliferation and extracellular matrix synthesis in human renal mesangial cells in vitro" 37 : 228-234, 2016

115 Gilbert RE, "Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor" 79 : 1312-1321, 2011

116 Yanda MK, "Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca2 in knock-out mouse models of polycystic kidney disease" 292 : 17897-17908, 2017

117 Wang X, "Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy" 86 : 712-725, 2014

118 Pang M, "Histone deacetylase 1/2 mediates proliferation of renal interstitial fibroblasts and expression of cell cycle proteins" 112 : 2138-2148, 2011

119 Iso T, "HES and HERP families: multiple effectors of the Notch signaling pathway" 194 : 237-255, 2003

120 Kovacs JJ, "HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor" 18 : 601-607, 2005

121 Kim MJ, "HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells" 32 : 3161-3168, 2012

122 Brilli LL, "HDAC inhibitors in kidney development anddisease" 28 : 1909-1921, 2013

123 Manson SR, "HDAC dependent transcriptional repression of Bmp-7 potentiates TGF-${\beta}$ mediated renal fibrosis in obstructive uropathy" 191 : 242-252, 2014

124 Igarashi P, "Genetics and pathogenesis of polycystic kidney disease" 13 : 2384-2398, 2002

125 Liu N, "Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis" 23 : 854-867, 2012

126 Coqueret O, "Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1" 275 : 18794-18800, 2000

127 Qian Y, "From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy" 57 : 1439-1445, 2008

128 Kobayashi T, "Expression and function of the Delta-1/Notch-2/Hes-1 pathway during experimental acute kidney injury" 73 : 1240-1250, 2008

129 Michishita E, "Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins" 16 : 4623-4635, 2005

130 Bielesz B, "Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans" 120 : 4040-4054, 2010

131 Wang XF, "Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma" 11 : 3535-3542, 2005

132 Berthier CC, "Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy" 58 : 469-477, 2009

133 Freidkin I, "Effects of histone deacetylase inhibitors on rat mesangial cells" 298 : F426-F434, 2010

134 Juengel E, "Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro" 105 : 549-557, 2010

135 Kinugasa F, "Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model" 21 : 198-202, 2009

136 Roskoski R Jr, "ERK1/2 MAP kinases: structure, function, and regulation" 66 : 105-143, 2012

137 Wei Y, "Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation" 4 : 949-951, 2008

138 Cha TL, "Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells" 15 : 840-850, 2009

139 Wilhelm S, "Discovery and development of sorafenib: a multikinase inhibitor for treating cancer" 5 : 835-844, 2006

140 Turner MD, "Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease" 1843 (1843): 2563-2582, 2014

141 Hori S, "Control of regulatory T cell development by the transcription factor Foxp3" 299 : 1057-1061, 2003

142 Sarkar S, "Complex inhibitory effects of nitric oxide on autophagy" 43 : 19-32, 2011

143 Van Beneden K, "Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis" 271 : 276-284, 2013

144 Verheul HM, "Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors" 14 : 3589-3597, 2008

145 Sato A, "Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells" 76 : 764.e7-764.e13, 2010

146 Walsh DW, "Co-regulation of Gremlin and Notch signalling in diabetic nephropathy" 1782 : 10-21, 2008

147 Gao L, "Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family" 277 : 25748-25755, 2002

148 Levine MH, "Class-specific histone/protein deacetylase inhibition protects against renal ischemia reperfusion injury and fibrosis formation" 15 : 965-973, 2015

149 Bertos NR, "Class II histone deacetylases: structure, function, and regulation" 79 : 243-252, 2001

150 Choi SY, "Class IHDACs specifically regulate E-cadherin expression in human renal epithelial cells" 20 : 2289-2298, 2016

151 Fritzsche FR, "Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer" 8 : 381-, 2008

152 Park JH, "Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation" 10 : 5271-5281, 2004

153 Regna NL, "Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo" 151 : 29-42, 2014

154 Tang J, "Class I HDAC activity is required for renal protection and regeneration after acute kidney injury" 307 : F303-F316, 2014

155 Shi Y, "Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China" 10 : 69-, 2017

156 Cao Y, "Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models" 106 : 21819-21824, 2009

157 Naesens M, "Calcineurin inhibitor nephrotoxicity" 4 : 481-508, 2009

158 Wang RN, "Bone morphogenetic protein (BMP) signaling in development and human diseases" 1 : 87-105, 2014

159 Liu N, "Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling" 8 : e54001-, 2013

160 Ponnusamy M, "Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy" 350 : 243-256, 2014

161 Liu Q, "Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215" 279 : 52175-52182, 2004

162 Sato A, "Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells" 19 : 217-223, 2011

163 Yung S, "Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis" 21 : 1912-1927, 2010

164 Yanda MK, "An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease" 313 : F997-F1004, 2017

165 Cargnello M, "Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases" 75 : 50-83, 2011

166 Juengel E, "Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells" 324 : 83-90, 2012

167 Hainsworth JD, "A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma" 29 : 451-455, 2011

168 Stadler WM, "A phase II study of depsipeptide in refractory metastatic renal cell cancer" 5 : 57-60, 2006

169 Banerji U, "A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors" 18 : 2687-2694, 2012

170 Kim MK, "A novel hydroxamic acid derivative, MHY218, induces apoptosis and cell cycle arrestthrough downregulation of NF-${\kappa}B$ in HCT116 human colon cancer cells" 44 : 256-264, 2014

171 Kwon HK, "A novel gamma-lactam-based histone deacetylase inhibitor potently inhibits the growth of human breast and renal cancer cells" 32 : 1723-1727, 2009

172 Hsing CH, "${\alpha}2$-Adrenoceptor agonist dexmedetomidine protects septic acute kidney injury through increasing BMP-7 and inhibiting HDAC2 and HDAC5" 303 : F1443-F1453, 2012